These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9498829)

  • 1. In vivo influence of p53 status on proliferation and chemoradiosensitivity in non-small-cell lung cancer.
    Perdomo JA; Naomoto Y; Haisa M; Fujiwara T; Hamada M; Yasuoka Y; Tanaka N
    J Cancer Res Clin Oncol; 1998 Jan; 124(1):10-8. PubMed ID: 9498829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice.
    Perez-Soler R; Kemp B; Wu QP; Mao L; Gomez J; Zeleniuch-Jacquotte A; Yee H; Lee JS; Jagirdar J; Ling YH
    Clin Cancer Res; 2000 Dec; 6(12):4932-8. PubMed ID: 11156254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model.
    Fujiwara T; Cai DW; Georges RN; Mukhopadhyay T; Grimm EA; Roth JA
    J Natl Cancer Inst; 1994 Oct; 86(19):1458-62. PubMed ID: 8089864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer.
    Wouters BG; Wang LH; Brown JM
    Ann Oncol; 1999; 10 Suppl 5():S29-33. PubMed ID: 10582136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-controlled p53 gene therapy for human non-small cell lung cancer xenografts in athymic nude mice via the CArG elements.
    Wang WD; Li R; Chen ZT; Li DZ; Duan YZ; Cao ZH
    Cancer Sci; 2005 Oct; 96(10):706-12. PubMed ID: 16232203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of tumor necrosis factor alpha and interferon alpha induces apoptotic cell death through a c-myc-dependent pathway in p53 mutant H226br non-small-cell lung cancer cell line.
    Yasuoka Y; Naomoto Y; Yamatsuji T; Takaoka M; Kimura M; Uetsuka H; Matsubara N; Fujiwara T; Gunduz M; Tanaka N; Haisa M
    Exp Cell Res; 2001 Dec; 271(2):214-22. PubMed ID: 11716533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer.
    Nemunaitis J; Swisher SG; Timmons T; Connors D; Mack M; Doerksen L; Weill D; Wait J; Lawrence DD; Kemp BL; Fossella F; Glisson BS; Hong WK; Khuri FR; Kurie JM; Lee JJ; Lee JS; Nguyen DM; Nesbitt JC; Perez-Soler R; Pisters KM; Putnam JB; Richli WR; Shin DM; Walsh GL; Merritt J; Roth J
    J Clin Oncol; 2000 Feb; 18(3):609-22. PubMed ID: 10653876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor.
    King TC; Estalilla OC; Safran H
    Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):4-11. PubMed ID: 10210535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene.
    Inoue A; Narumi K; Matsubara N; Sugawara S; Saijo Y; Satoh K; Nukiwa T
    Cancer Lett; 2000 Aug; 157(1):105-12. PubMed ID: 10893449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
    Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
    J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer.
    Johnson EA; Klimstra DS; Herndon JE; Catalano E; Canellos GP; Graziano SL; Kern JA; Green MR
    Cancer Invest; 2002; 20(5-6):686-92. PubMed ID: 12197224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective targeting p53
    Lu W; Cheng F; Yan W; Li X; Yao X; Song W; Liu M; Shen X; Jiang H; Chen J; Li J; Huang J
    Oncogene; 2017 Aug; 36(33):4719-4731. PubMed ID: 28394340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
    Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
    Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
    Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
    Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
    Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
    Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
    Wu WG; Soria JC; Wang L; Kemp BL; Mao L
    Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-radiation induces non-small-cell lung cancer apoptosis by upregulation of Axin expression.
    Han Y; Wang Y; Xu HT; Yang LH; Wei Q; Liu Y; Zhang Y; Zhao Y; Dai SD; Miao Y; Yu JH; Zhang JY; Li G; Yuan XM; Wang EH
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):518-26. PubMed ID: 19735876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy.
    van de Vaart PJ; Belderbos J; de Jong D; Sneeuw KC; Majoor D; Bartelink H; Begg AC
    Int J Cancer; 2000 Mar; 89(2):160-6. PubMed ID: 10754494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.
    Lai SL; Perng RP; Hwang J
    J Biomed Sci; 2000; 7(1):64-70. PubMed ID: 10644891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.